Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.
Saved in:
| Title: | Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01. |
|---|---|
| Authors: | Azad AA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Agarwal N; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Armstrong AJ; Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC, USA., Hellmis E; Urologicum Duisburg, Center for Urology and Urologic Cancer, Duisburg, Germany., Sugimoto M; Department of Urology, Kagawa University, Kagawa, Japan., Ürün Y; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey., Xing N; Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Aregay M; Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Lima J; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK., Meulendijks D; Global Medicines Development, Oncology R&D, AstraZeneca, Barcelona, Spain., Chi KN; Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada. |
| Source: | Future oncology (London, England) [Future Oncol] 2026 Apr; Vol. 22 (10), pp. 1153-1163. Date of Electronic Publication: 2026 Apr 14. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
